Glioma-associated oncogene family zinc finger protein (GLI)

The Glioma-associated oncogene (GLI) transcription factors, comprising GLI1, GLI2, and GLI3, are the terminal nuclear effectors of the Hedgehog (Hh) signaling pathway, which is essential for embryonic development and tissue homeostasis (UniProt P08151, P10071). These proteins contain C2H2-type zinc finger domains that allow them to bind specific DNA sequences and regulate the transcription of genes involved in cell proliferation, differentiation, and stemness (NCBI Gene ID: 2735). In the canonical pathway, activation of the Smoothened receptor prevents the proteolytic cleavage of GLI proteins, allowing full-length activator forms to translocate to the nucleus and initiate transcription (PubMed: 27071618). Aberrant GLI activity is a key driver in several malignancies, most notably basal cell carcinoma and medulloblastoma, and is often associated with poor prognosis and epithelial-mesenchymal transition in solid tumors (PubMed: 30626305). Because GLI acts at the most downstream point of the Hedgehog pathway, it is an attractive therapeutic target for overcoming resistance to Smoothened (SMO) inhibitors like vismodegib. Small molecules such as GANT-61 and Glabrescione B have been developed to directly inhibit GLI DNA binding, while drugs like arsenic trioxide promote GLI protein degradation (PubMed: 21147147). Despite their therapeutic potential, the critical role of GLI in physiological processes like bone growth and wound healing presents significant challenges for systemic clinical application.

Other names

GLI family zinc finger proteinsGlioma-associated oncogene homologGLI transcription factorsHedgehog signaling pathway effectors

Inhibition of the Hedgehog signaling pathway by directly binding to GLI proteins to prevent DNA binding, inhibiting nuclear translocation, or inducing proteasomal degradation of GLI proteins.